Holen Sie sich die Stockscreener-App
3.21
1.58%
0.05
Handel nachbörslich:
3.21
Schlusskurs vom Vortag:
$3.16
Offen:
$3.18
24-Stunden-Volumen:
241.96K
Relative Volume:
0.56
Marktkapitalisierung:
$205.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.36M
KGV:
-0.7666
EPS:
-4.1875
Netto-Cashflow:
$-15.05M
1W Leistung:
-31.99%
1M Leistung:
-34.76%
6M Leistung:
-46.94%
1J Leistung:
-24.11%
1-Tages-Spanne:
$3.11
$3.26
1-Wochen-Bereich:
$3.11
$4.70
52-Wochen-Spanne:
$2.00
$6.35
Zura Bio Ltd Stock (ZURA) Company Profile
Firmenname
Zura Bio Ltd
Sektor
Branche
Telefon
858-247-0520
Adresse
4225 EXECUTIVE SQUARE, LA JOLLA
Vergleichen Sie ZURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ZURA | 3.21 | 205.67M | 0 | -60.36M | -15.05M | -4.1875 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-25 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Guggenheim | Buy |
| 2023-06-14 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-05-24 | Eingeleitet | Raymond James | Strong Buy |
Zura Bio Ltd Aktie (ZURA) Neueste Nachrichten
GREAT POINT PARTNERS LLC Reduces Stake in Zura Bio Ltd - GuruFocus.com
ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd - GuruFocus.com
Zura Bio advances Phase 2 study for systemic sclerosis treatment - Investing.com
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis - Yahoo Finance
Guggenheim maintains Buy on Zura Bio, target steady at $15 - Investing.com India
Guggenheim maintains Buy on Zura Bio, target steady at $15 By Investing.com - Investing.com UK
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - BioSpace
Zura Bio (NASDAQ:ZURA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com
Leerink Partners initiates Zura Bio stock with Outperform rating, $15 target - Investing.com
Zura Bio Ltd re-elects board, ratifies auditor at AGM By Investing.com - Investing.com Australia
Zura Bio to Participate in Two Upcoming Investor Conferences in November - Yahoo Finance
Zura Bio Ltd re-elects board, ratifies auditor at AGM - Investing.com India
Zura Bio announces departure of Chief Scientific Officer By Investing.com - Investing.com Australia
Zura Bio announces departure of Chief Scientific Officer - Investing.com India
Private equity firms among Zura Bio Limited's (NASDAQ:ZURA) largest shareholders, saw gain in holdings value after stock jumped 14% last week - Simply Wall St
Bullish Zura Bio Insiders Loaded Up On US$1.01m Of Stock - Yahoo Finance
Forefront Analytics LLC Has $145,000 Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Shares Sold by Affinity Asset Advisors LLC - Defense World
Should investors be concerned about Zura Bio Ltd (ZURA)? - US Post News
A stock that deserves closer examination: Zura Bio Ltd (ZURA) - US Post News
Institutions profited after Zura Bio Limited's (NASDAQ:ZURA) market cap rose US$45m last week but private equity firms profited the most - Yahoo Finance
Piper Sandler maintains Overweight rating on Zura Bio shares - Investing.com
Zura Bio Ltd [ZURA] Director makes an insider sale of 3,800,000 shares worth 10,260,000. - Knox Daily
Piper Sandler maintains Overweight rating on Zura Bio shares By Investing.com - Investing.com Australia
Zura Bio Ltd (ZURA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Zura Bio (NASDAQ:ZURA) versus Aligos Therapeutics (NASDAQ:ALGS) Critical Comparison - Defense World
A Guide To The Risks Of Investing In Zura Bio Ltd (ZURA) - Knox Daily
Have Zura Bio Insiders Been Selling Stock? - Simply Wall St
Zura Bio director Sidhu Someit sells shares worth over $200,000 - Investing.com
Taking a look at what insiders are doing to gauge the Zura Bio Ltd (ZURA)’s direction - Knox Daily
Zura Bio to Present at Three Upcoming Investor Conferences in September - Yahoo Finance
Zura Bio Ltd [ZURA] Stock bought by Insider Ploos van Amstel Arnout for $0.5 million - Knox Daily
Get in on Zura Bio Ltd’s (ZURA) buy-in window today! - SETE News
Zura Bio Ltd (ZURA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Zura Bio issues warrants after share surrender - Investing.com India
Zura Bio Ltd [ZURA] Investment Guide: What You Need to Know - Knox Daily
Chardan Capital Comments on Zura Bio Limited’s FY2024 Earnings (NASDAQ:ZURA) - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Zura Bio (NASDAQ:ZURA) - Defense World
Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Lelezard
Zura Bio Limited (NASDAQ:ZURA) Sees Significant Increase in Short Interest - Defense World
Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants - Yahoo Finance
Trading Day Triumph: Zura Bio Ltd (ZURA) Ends at 3.39, a -4.24 Surge/Plunge - The Dwinnex
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Buy” by Analysts - Defense World
Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants - Yahoo Finance
Insider Buyers At Zura Bio Likely Disappointed With 11% Slide - Simply Wall St
Investing in Zura Bio Ltd (ZURA): What You Must Know - Knox Daily
Zura Bio Names Robert Lisicki As CEO & Director Of The Board - Contract Pharma
Zura Bio Ltd (ZURA) rating initates by Piper Sandler - Knox Daily
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 152.1% in July - Defense World
Zura Bio Ltd reaches settlement with former CEO - Investing.com India
Finanzdaten der Zura Bio Ltd-Aktie (ZURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):